The Czech Republic is one of the few countries in the CEE region where public allocations for healthcare were not affected by the 2008 global financial crisis. In fact, per capita expenditures on healthcare and pharmaceuticals are comparable to those of developed countries.  The Czech Republic is one of the largest pharmaceutical exporters in the CEE region.  It is also home to several world-class R&D centers and is the 3rd largest market for clinical trials in the region.

  • What are the driving forces behind the Czech Republic's well -developed clinical trial industry?

  • How are recent reforms in pharmaceutical pricing and reimbursement influencing investments in pharmaceutical sales?

  • How will the establishment of specialized R&D clusters support innovation in Oncology and Immunology research?

Our report offers in-depth insight into the Czech Republic's macroeconomic environment, healthcare sector, pharmaceutical market, clinical trial industry, R&D activities, and recent business alliances & investments.

It provides you with a clear Roadmap for Business Growth based on the following proprietary tools:


EXECUTIVE SUMMARY

TABLES & GRAPHS

GLOSSARY

I.          COUNTRY OVERVIEW

II.        MACROECONOMIC & SOCIAL OUTLOOK

a.   MACROECONOMICS

b.   BUSINESS ENVIRONMENT

c.   SOCIAL OUTLOOK

III.       HEALTHCARE DEVELOPMENTS

a.   OVERVIEW

b.   PROVISION

c.   EXPENDITURE RATIOS

d.   PERSONNEL & INFRASTRUCTURE

e.   DISEASE BURDEN

IV.       MARKET ACCESS

a.   REGISTRATION

b.   PRICING & REIMBURSEMENT

V.        PHARMACEUTICAL OUTLOOK

a.   OVERVIEW

b.   PHARMACEUTICAL MARKET

c.   LEADING PHARMACEUTICAL COMPANIES

d.   MANUFACTURING & TRADE

VI.       COMPLIANCE

a.   MARKETING PRACTICES

b.   CLINICAL TRIALS

VII.     RESEARCH & DEVELOPMENT

a.   R&D FUNDS BY SOURCE

b.   PHARMA SHARE IN R&D

VIII.    CROs / CLINICAL TRIALS

IX.       ALLIANCES & INVESTMENTS

X.        CONCLUDING REMARKS

Table 1. Demographics in the Czech Republic, 2013
Table 2. Inventory of medical devices, 2011

Figure 1: Breakdown of government expenditures, 2013
Figure 2: FDI inflows by country, 2013
Figure 3: FDI inflows by sector, 2013
Figure 4: Health expenditures, 2012
Figure 5: Major causes of death, 2009
Figure 6: Volume of registered, traded, and reimbursed medicine variations, 2009-2013
Figure 7: Share of drug sales by category, 2013
Figure 8: Drug market trends, 2010-2018
Figure 9: Production of pharmaceuticals and medicinal chemicals, 2008 - 2013
Figure 10: Pharmaceutical trade, 2004-2013
Figure 11: Pharmaceutical export partners, 2013
Figure 12: Pharmaceutical import partners, 2013
Figure 13: R&D funds by source, 2012
Figure 14: Pharmaceutical publications by category, 2013
Figure 15: Clinical trials applications received by the SUKL, 2011-2013
Figure 16: Clinical trials by therapeutic area, 2013

Order Report

Please fill out the form below. A sales representative will
get back to you very shortly.

First Name*

E-mail Address*

Company*

Country*

Requested Report

Last Name*

Phone Number*

Position*

City*

Verification*

Details